ABIOMED, Inc. (ABMD) Receives $325.00 Average PT from Brokerages
ABIOMED, Inc. (NASDAQ:ABMD) has been assigned a consensus rating of “Buy” from the twelve research firms that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $325.00.
A number of equities analysts have recently issued reports on the company. Piper Jaffray Companies upped their price objective on ABIOMED to $360.00 and gave the stock an “overweight” rating in a report on Thursday, May 3rd. ValuEngine upgraded ABIOMED from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 3rd. Zacks Investment Research upgraded ABIOMED from a “hold” rating to a “buy” rating and set a $338.00 price objective for the company in a report on Thursday, May 3rd. Morgan Stanley upped their price objective on ABIOMED from $259.00 to $320.00 and gave the stock an “equal weight” rating in a report on Tuesday, May 1st. Finally, Goldman Sachs Group assumed coverage on ABIOMED in a report on Wednesday, April 4th. They issued a “buy” rating and a $332.00 price objective for the company.
In related news, SVP William J. Bolt sold 22,790 shares of the stock in a transaction dated Monday, May 7th. The stock was sold at an average price of $348.03, for a total transaction of $7,931,603.70. Following the completion of the sale, the senior vice president now directly owns 66,414 shares in the company, valued at approximately $23,114,064.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Martin P. Sutter sold 21,890 shares of the stock in a transaction dated Tuesday, May 8th. The shares were sold at an average price of $343.50, for a total value of $7,519,215.00. Following the sale, the director now owns 46,668 shares of the company’s stock, valued at $16,030,458. The disclosure for this sale can be found here. Insiders have sold a total of 62,180 shares of company stock valued at $21,542,744 over the last 90 days. 7.00% of the stock is currently owned by company insiders.
Shares of ABIOMED traded down $0.18, reaching $394.28, during midday trading on Friday, according to MarketBeat. The stock had a trading volume of 388,427 shares, compared to its average volume of 625,980. ABIOMED has a 12-month low of $134.80 and a 12-month high of $403.45. The stock has a market capitalization of $17.46 billion, a P/E ratio of 160.93, a PEG ratio of 4.25 and a beta of 0.18.
ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, May 3rd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. ABIOMED had a return on equity of 17.58% and a net margin of 18.89%. The firm had revenue of $174.44 million during the quarter, compared to analysts’ expectations of $164.30 million. During the same period in the prior year, the business earned $0.33 EPS. The company’s revenue for the quarter was up 39.9% compared to the same quarter last year. research analysts expect that ABIOMED will post 3.43 EPS for the current fiscal year.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.